New Alzheimer's Medication: Kisunla - What You Need to Know

The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials. Dr. Pauldurai will talk about the new drug, benefits, and answer questions you may have about it. Presenter Dr. Jennifer Pauldurai, MD